Résumé
<p><b>OBJECTIVE</b>To study the clinical efficacy of cellular immunotherapy combined with bortezomib for treatment of patients with multiple myeloma.</p><p><b>METHODS</b>A total of 76 patients with multiple myeloma in our hospital from October 2012 to October 2013 were selected and randomly divided into 2 groups: the patients in 1 group (38 cases) were treated with cellular immunotherapy combined with chemotherapy including bortezomib (combined therapy group), the patients in other group(38 cases) were treated with only chemotherapy including bortezomib(single chemotherapy as control group). The treatment remission rate, the expression changes of immunophenotype, progression-free survival(PFS) and adverse reactions were compared in the 2 groups.</p><p><b>RESULTS</b>The total remission rate of combined therapy group was significantly higher than that in the control group (P<0.05); the positive rates of CD38, CD56and CD138in combined therapy group were all significantly lower than those in control group, and the CD19was significantly higher (P<0.05). The PFS rates of 1, 2 and 3 years in the combined therapy group were all significantly higher than those in the control group (P<0.05). The incidence of fatigue, rash, peripheral neuropathy, anemia and granulocyte deficiency in the combined therapy group was all significantly lower than that in the control group (P<0.05).</p><p><b>CONCLUSION</b>Cellular immunotherapy combined with bortezomib can significantly improve the remission rate, prolong survival, and significantly decrease adverse event rate of multiple myeloma patients.</p>
Résumé
<p><b>OBJECTIVE</b>To evaluate the therapeutic and adverse effects of topotecan combined with cisplatin in the treatment of advanced squamous cell lung cancer and head and neck cancer.</p><p><b>METHODS</b>Totally 126 patients with advanced squamous cell lung cancer and head and neck cancer, which were confirmed by tissue pathology or cytopathology, were treated with intravenous infusion of topotecan at the dose of 0.75-1.2 mg/m2 (for 5 consecutive days) combined with intravenous infusion of cisplantin at 25-30 mg/m2 for 3 consecutive days. Each treatment course consisted of two 21-day cycles of the treatment.</p><p><b>RESULTS</b>No complete remission was achieved in these patients, and 61 patients had partial remission, 53 had clinically stabilized disease and 12 had progressive disease. The total response rate was 48.4% among the patients, with the median survival time of 10.1 months and one-year survival rate of 36.7%. The major adverse effects were bone marrow suppression and alopecia.</p><p><b>CONCLUSION</b>Topotecan combined with cisplatin may achieve a favorable response in patients with advanced squamous cell lung cancer and head and neck cancer, and causes tolerable adverse effect without accumulative toxicity.</p>